Literature DB >> 31872060

Human Pharmacokinetic Parameters of Orally Administered Δ9-Tetrahydrocannabinol Capsules Are Altered by Fed Versus Fasted Conditions and Sex Differences.

Stephanie Lunn1, Patrick Diaz2, Shannon O'Hearn2, Shaina P Cahill1, Alexia Blake2, Kelly Narine1, Jason R B Dyck1,3.   

Abstract

Background: There is variability in the reported Δ9-tetrahydrocannabinol (THC) and 11-hydroxy-tetrahydrocannabinol (11-OH-THC) pharmacokinetic (PK) and pharmacodynamic (PD) parameters between studies and there is limited investigation into how the presence of food or sex affect these parameters. In this study, we examined the PK and PD parameters of an encapsulated THC extract and its major active metabolite, 11-OH-THC, under different fed states.
Methods: The study was a single-dose, randomized, double-blinded, four-way crossover investigation. THC capsules (1 or 2×5 mg) were administered to 28 healthy adults (13 females: 15 males) under a fasted condition or after a high-fat meal. Blood samples were collected and PK parameters were determined through noncompartmental analysis. Adverse events (AEs), cognitive function (through completion of digit symbol substitution tests), blood pressure, and heart rate were also recorded.
Results: The presence of high-fat food significantly enhanced time to peak plasma concentration (T max) and area under the curve (AUC0-24) for both THC and 11-OH-THC and reduced THC's apparent volume of distribution (V z/F) and apparent clearance (Cl/F). Females had a significantly greater peak plasma concentration (C max) compared with males after 5 mg THC in a fasted state. No cardiovascular or cognitive effects and only mild AEs (somnolence, fatigue, and euphoric mood) were reported.
Conclusion: These findings may help to inform the guidelines provided by governing health bodies on the effects of cannabis, such as time to onset and duration of action, and aid health care practitioners in their prescribing practices. Furthermore, the doses used in this study are safe to consider for future interventional studies in disease conditions where THC has been shown to have therapeutic efficacy. Copyright 2019, Mary Ann Liebert, Inc., publishers.

Entities:  

Keywords:  11-OH-THC; THC; fasted; fed; pharmacokinetic; sex

Year:  2019        PMID: 31872060      PMCID: PMC6922062          DOI: 10.1089/can.2019.0037

Source DB:  PubMed          Journal:  Cannabis Cannabinoid Res        ISSN: 2378-8763


  26 in total

Review 1.  Polymorphism of human cytochrome P450 enzymes and its clinical impact.

Authors:  Shu-Feng Zhou; Jun-Ping Liu; Balram Chowbay
Journal:  Drug Metab Rev       Date:  2009       Impact factor: 4.518

2.  Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.

Authors:  Thomas Nadulski; Fritz Pragst; Gordon Weinberg; Patrik Roser; Martin Schnelle; Eva-Maria Fronk; Andreas Michael Stadelmann
Journal:  Ther Drug Monit       Date:  2005-12       Impact factor: 3.681

3.  Base rate data for the WAIS-R: test-retest stability and VIQ-PIQ differences.

Authors:  J D Matarazzo; D O Herman
Journal:  J Clin Neuropsychol       Date:  1984-11

4.  Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6.

Authors:  Satoshi Yamaori; Yasuka Okamoto; Ikuo Yamamoto; Kazuhito Watanabe
Journal:  Drug Metab Dispos       Date:  2011-08-05       Impact factor: 3.922

Review 5.  Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science.

Authors:  Eric P Baron
Journal:  Headache       Date:  2018-07       Impact factor: 5.887

6.  Tetrahydrocannabinol Does Not Reduce Pain in Patients With Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study.

Authors:  Marjan de Vries; Dagmar C M van Rijckevorsel; Kris C P Vissers; Oliver H G Wilder-Smith; Harry van Goor
Journal:  Clin Gastroenterol Hepatol       Date:  2016-10-05       Impact factor: 11.382

7.  Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana.

Authors:  M A Huestis; J E Henningfield; E J Cone
Journal:  J Anal Toxicol       Date:  1992 Sep-Oct       Impact factor: 3.367

8.  Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking.

Authors:  A Ohlsson; J E Lindgren; A Wahlen; S Agurell; L E Hollister; H K Gillespie
Journal:  Clin Pharmacol Ther       Date:  1980-09       Impact factor: 6.875

9.  Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.

Authors:  Sebastian Walther; Richard Mahlberg; Uta Eichmann; Dieter Kunz
Journal:  Psychopharmacology (Berl)       Date:  2006-03-07       Impact factor: 4.530

10.  Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women.

Authors:  M E Wall; B M Sadler; D Brine; H Taylor; M Perez-Reyes
Journal:  Clin Pharmacol Ther       Date:  1983-09       Impact factor: 6.875

View more
  7 in total

1.  Sex differences in the acute effects of intravenous (IV) delta-9 tetrahydrocannabinol (THC).

Authors:  Anahita Bassir Nia; Maria J Orejarena; Leigh Flynn; Christina Luddy; Deepak Cyril D'Souza; Patrick D Skosnik; Brian Pittman; Mohini Ranganathan
Journal:  Psychopharmacology (Berl)       Date:  2022-04-19       Impact factor: 4.530

2.  Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations.

Authors:  Catherine F Moore; Elise M Weerts
Journal:  Psychopharmacology (Berl)       Date:  2021-10-15       Impact factor: 4.415

3.  Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials.

Authors:  Thomas R Arkell; Richard C Kevin; Frederick Vinckenbosch; Nicholas Lintzeris; Eef Theunissen; Johannes G Ramaekers; Iain S McGregor
Journal:  Addict Biol       Date:  2021-12-22       Impact factor: 4.093

4.  Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Yellow Oil in Healthy Participants.

Authors:  Erica N Peters; Irina Mosesova; Laura MacNair; Ryan Vandrey; M Hunter Land; Mark A Ware; Cynthia Turcotte; Marcel O Bonn-Miller
Journal:  J Anal Toxicol       Date:  2022-04-21       Impact factor: 3.220

5.  Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants.

Authors:  Erica N Peters; Irina Mosesova; Laura MacNair; Ryan Vandrey; M Hunter Land; Mark A Ware; Cynthia Turcotte; Marcel O Bonn-Miller
Journal:  J Anal Toxicol       Date:  2022-05-20       Impact factor: 3.220

Review 6.  Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions.

Authors:  Jeremy D Henson; Luis Vitetta; Sean Hall
Journal:  Inflammopharmacology       Date:  2022-07-07       Impact factor: 5.093

7.  Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters.

Authors:  José A Crippa; Luiz C Pereira Junior; Lívia C Pereira; Patrícia M Zimmermann; Liberato Brum Junior; Letícia M Rechia; Isabella Dias; Jaime E Hallak; Alline C Campos; Francisco S Guimarães; Regina H Queiroz; Antonio W Zuardi
Journal:  Braz J Psychiatry       Date:  2022 Jan-Feb       Impact factor: 2.697

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.